The CARI program and overcoming commercialization challenges in the Canadian isotope sector

June 17, 2021 CPDC

CARI is a collaboration between The Centre for Probe Development and Commercialization (CPDC) and adMare BioInnovations (adMare) working to bring respective resources together to advance an area of tremendous therapeutic and commercial potential in which Canada can gain considerable global competitive advantage in radiopharmaceuticals.

Join us for this event where we will learn how the CARI program is exploring opportunities arising from academic discoveries and early enterprises, establishing rigorous drug development programs around selected opportunities, and driving the generation of proof-of-principle for the commercialization of new radiopharmaceutical assets.

The event will be taking place on June 23 @ 11 a.m. EST. Please register at the link below.

Dr. Bruno Paquin

Dr. Ghadeer Shubassi
Senior Business Development Manager

Yasamin Allahverdi
Business Analyst

Dr. Stuart Cain
Associate Director, Scientific Evaluation
adMare BioInnovations

Dr. Lana Janes
Venture Partner
adMare BioInnovations

Eric Cruz
Associate Scientist, Biologics
adMare BioInnovations

James Scongack
EVP, Bruce Power
Chair, Canadian Nuclear Isotope Council

Andrew Thiele
Director Strategic Initiatives
Canadian Nuclear Isotopes Council

More news from CPDC

AtomVie Global Radiopharma Inc. Announces its Spinout and Series A Financing with Avego

HAMILTON ON, Aug. 24, 2022 – AtomVie Global Radiopharma Inc. (“AtomVie”) today announced the successful closing of its Series A financing with Avego Management, LLC (“Avego”), a healthcare investment firm. AtomVie is a global leading CDMO (Contract Development and Manufacturing Organization) for the development, manufacturing, and global distribution of radiopharmaceuticals and has received a financing commitment of at

CPDC executes its first commercial sublicensing agreement with Lawson Health Research Institute for PSMA-1007, expanding access to the prostate cancer diagnostic agent in Ontario

HAMILTON, ON, June 28, 2022 /CNW/ – The Centre for Probe Development and Commercialization (CPDC), a global leader in the development, production and commercialization of radiopharmaceuticals, has licensed [18F]PSMA-1007 from ABX- advanced biochemical compounds GmbH (Radeberg, Germany) and will hold the exclusive license to manufacture, commercialize and distribute the imaging agent in Canada. Concurrently, CPDC is also pleased to

Isotopia and CPDC Successfully Deliver First Doses of n.c.a. Lu-177 to North American Customers

Isotopia and CPDC shorten arrival time to patients. The production and supply in Canada are designed to address the growing need for no-carrier-added Lutetium-177 (n.c.a. Lu-177) in North America.

For more information contact us at: